Adaptimmune Annual report pursuant to Section 13 and 15(d)

Revenue (Details)

Revenue (Details) $ in Thousands, £ in Millions	1 Months Ended		6 Months Ended	12 Months Ended
Revenue (Details) $ in Thousands, £ in Millions	Jun. 30, 2014 GBP (£)	Jun. 30, 2014 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) item	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)
Collaboration and License Agreement
Revenue recognized			$ 8,979					$ 14,198	$ 9,871	$ 825
GlaxoSmithKline Intellectual Property Development Ltd \| Change in service delivery period in collaboration and license agreement
Collaboration and License Agreement
Revenue recognized			8,979					$ 14,198
GlaxoSmithKline Intellectual Property Development Ltd \| Change in service delivery period in collaboration and license agreement \| Forecast adjustment
Collaboration and License Agreement
Revenue recognized				$ 6,053	$ 900	$ 939	$ (2,237)
Collaborative arrangement \| GlaxoSmithKline Intellectual Property Development Ltd
Collaboration and License Agreement
Number of additional target peptides, that the entity has right to nominate \| item								3
Upfront payment received	£ 25	$ 42,100
Amount of non-substantive development milestones			$ 14,400					$ 17,400	7,200
Royalties received								$ 0
Written notice period required to be served for the termination of agreement for material breach (in days)								60 days
Notice period required to be served for the termination of agreement or specific program (in days)								60 days
Maximum combination studies permitted \| item								8
Revenue recognized								$ 8,979	$ 9,871	$ 825
Collaborative arrangement \| GlaxoSmithKline Intellectual Property Development Ltd \| Adjustment
Collaboration and License Agreement
Revenue recognized								$ (5,615)